1.25
price down icon3.10%   -0.04
after-market 시간 외 거래: 1.25
loading
전일 마감가:
$1.29
열려 있는:
$1.29
하루 거래량:
74,182
Relative Volume:
0.68
시가총액:
$37.92M
수익:
-
순이익/손실:
$-60.70M
주가수익비율:
-0.6127
EPS:
-2.04
순현금흐름:
$-61.05M
1주 성능:
-0.79%
1개월 성능:
-16.67%
6개월 성능:
+16.82%
1년 성능:
-45.18%
1일 변동 폭
Value
$1.22
$1.29
1주일 범위
Value
$1.22
$1.3252
52주 변동 폭
Value
$0.87
$3.07

An 2 Therapeutics Inc Stock (ANTX) Company Profile

Name
명칭
An 2 Therapeutics Inc
Name
전화
(650) 331-9090
Name
주소
1800 EL CAMINO REAL, SUITE D, MENLO PARK
Name
직원
36
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
ANTX's Discussions on Twitter

ANTX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ANTX
An 2 Therapeutics Inc
1.25 37.92M 0 -60.70M -61.05M -2.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 125.74B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.57B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.40B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.36B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.89B 3.81B -644.79M -669.77M -6.24

An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-08-09 다운그레이드 Evercore ISI In-line → Underperform
2024-08-09 다운그레이드 Leerink Partners Outperform → Market Perform
2024-07-03 업그레이드 Leerink Partners Market Perform → Outperform
2024-04-02 업그레이드 JMP Securities Mkt Perform → Mkt Outperform
2024-02-13 다운그레이드 Leerink Partners Outperform → Market Perform
2024-02-12 다운그레이드 Evercore ISI Outperform → In-line
2024-02-12 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2024-02-12 다운그레이드 Oppenheimer Outperform → Perform
2024-01-04 개시 JMP Securities Mkt Outperform
2022-07-18 재개 Oppenheimer Outperform
모두보기

An 2 Therapeutics Inc 주식(ANTX)의 최신 뉴스

pulisher
Apr 23, 2025

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting - Yahoo Finance

Apr 23, 2025
pulisher
Apr 23, 2025

Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025 - Yahoo Finance

Apr 23, 2025
pulisher
Apr 21, 2025

Coya Therapeutics, Inc. Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) - marketscreener.com

Apr 21, 2025
pulisher
Apr 18, 2025

Viking Therapeutics (NasdaqCM:VKTX) Completes Enrollment For Phase 2 Trial Of VK2735 - Yahoo Finance

Apr 18, 2025
pulisher
Apr 14, 2025

Verve Therapeutics Announces Positive Initial Data from the - GlobeNewswire

Apr 14, 2025
pulisher
Apr 10, 2025

Cyrano Therapeutics Completes Enrollment in Phase 2 FLAVOR Trial of CYR-064 for Post-Viral Smell Loss - Yahoo Finance

Apr 10, 2025
pulisher
Apr 09, 2025

KSQ Therapeutics Announces First Patient Dosed in Phase 1/2 - GlobeNewswire

Apr 09, 2025
pulisher
Apr 07, 2025

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data For Lx2006 In Friedreich Ataxia Cardiomyopathy Supporting Advancement To Registrational Study - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study - GlobeNewswire

Apr 07, 2025
pulisher
Apr 05, 2025

NMRA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit - The Malaysian Reserve

Apr 05, 2025
pulisher
Apr 04, 2025

Alaunos Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance

Apr 04, 2025
pulisher
Apr 04, 2025

Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting - Yahoo Finance

Apr 04, 2025
pulisher
Apr 03, 2025

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance - GlobeNewswire

Apr 03, 2025
pulisher
Apr 03, 2025

Intellia Therapeutics Announces First Patient Dosed in the - GlobeNewswire

Apr 03, 2025
pulisher
Apr 02, 2025

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program - GlobeNewswire

Apr 02, 2025
pulisher
Apr 02, 2025

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - BioSpace

Apr 02, 2025
pulisher
Mar 31, 2025

Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights - Yahoo Finance

Mar 31, 2025
pulisher
Mar 28, 2025

Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 27, 2025

Yoda Therapeutics Announces First Patient Dosed in Phase 2 Trial of YA-101 for Multiple System Atrophy - BioSpace

Mar 27, 2025
pulisher
Mar 26, 2025

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - Quantisnow

Mar 26, 2025
pulisher
Mar 26, 2025

Major Milestone: Viking's Oral Weight Loss Drug Advances with 280-Patient Phase 2 Trial - Stock Titan

Mar 26, 2025
pulisher
Mar 25, 2025

iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 - Yahoo Finance

Mar 25, 2025
pulisher
Mar 25, 2025

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Oncotelic Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 Conference - GlobeNewswire

Mar 25, 2025
pulisher
Mar 20, 2025

Cognition Therapeutics, Inc. Reports Positive Phase 2 Results for Zervimesine in Dementia with Lewy Bodies and Alzheimer's Disease, Plans Advancement to Late-Stage Trials - Nasdaq

Mar 20, 2025
pulisher
Mar 18, 2025

EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors - Yahoo Finance

Mar 18, 2025
pulisher
Mar 17, 2025

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Ex - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia - Yahoo Finance

Mar 17, 2025
pulisher
Mar 16, 2025

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months - Yahoo Finance

Mar 16, 2025
pulisher
Mar 16, 2025

Dyne Therapeutics Announces New Long-Term Clinical Data - GlobeNewswire

Mar 16, 2025
pulisher
Mar 13, 2025

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial - PR Newswire

Mar 13, 2025
pulisher
Mar 12, 2025

Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) Launch First Phase 2 Combination Trial for Sapanisertib-Serabelisib in Patients With Endometrial Cancer - Business Wire

Mar 12, 2025
pulisher
Mar 10, 2025

Sun Pharma Shares Gain 2% on Plans to Acquire Checkpoint Therapeutics - Equitypandit

Mar 10, 2025
pulisher
Mar 10, 2025

Latest News | Sun Pharma Shares Rise over 2 Pc as Company to Acquire Checkpoint Therapeutics - LatestLY

Mar 10, 2025
pulisher
Mar 06, 2025

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib - GlobeNewswire

Mar 06, 2025
pulisher
Mar 06, 2025

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration - Yahoo Finance

Mar 06, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing - GlobeNewswire

Mar 05, 2025
pulisher
Mar 04, 2025

HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open - Yahoo Finance

Mar 04, 2025
pulisher
Mar 03, 2025

White & Case advises Helix Acquisition Corp. II on its US$949 million business combination with BridgeBio Oncology Therapeutics - White & Case LLP

Mar 03, 2025
pulisher
Mar 02, 2025

Why Akero Therapeutics, Inc. (AKRO) is Skyrocketing So Far in 2025 - Insider Monkey

Mar 02, 2025
pulisher
Mar 02, 2025

Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 - Insider Monkey

Mar 02, 2025
pulisher
Mar 01, 2025

Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025 - Yahoo Finance

Mar 01, 2025
pulisher
Feb 28, 2025

Candel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial resultsICYMI - Proactive Investors USA

Feb 28, 2025
pulisher
Feb 28, 2025

BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines - Business Wire

Feb 28, 2025
pulisher
Feb 27, 2025

Silver Bullet Therapeutics Announces Podcast Scheduled to Air on March 2, 2025 - Yahoo Finance

Feb 27, 2025
pulisher
Feb 27, 2025

Intellia Therapeutics Announces Fourth Quarter and - GlobeNewswire

Feb 27, 2025
pulisher
Feb 26, 2025

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates - Yahoo Finance

Feb 26, 2025
pulisher
Feb 25, 2025

Medicenna Therapeutics Corp. - Baystreet.ca

Feb 25, 2025

An 2 Therapeutics Inc (ANTX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

An 2 Therapeutics Inc 주식 (ANTX) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Chanda Sanjay
Chief Development Officer
Jan 03 '25
Sale
1.34
2,957
3,965
29,824
Prior Stephen David
Chief Strategy Officer
Jan 03 '25
Sale
1.34
2,029
2,721
33,313
Eizen Joshua M
See Remarks
Jan 03 '25
Sale
1.34
9,663
12,958
116,672
Readnour Robin Shane
Director
Dec 09 '24
Buy
1.43
30,772
43,984
647,573
Readnour Robin Shane
Director
Dec 06 '24
Buy
1.45
19,228
27,795
629,090
Readnour Robin Shane
Director
Dec 10 '24
Buy
1.49
10,000
14,930
652,573
Readnour Robin Shane
Director
Nov 27 '24
Buy
1.42
50,000
70,840
622,573
Readnour Robin Shane
Director
Nov 26 '24
Buy
1.39
25,000
34,845
597,573
Zakrzewski Joseph S
Director
Nov 27 '24
Buy
1.40
2,000
2,800
125,199
Readnour Robin Shane
Director
Nov 19 '24
Buy
1.04
150,000
155,258
560,073
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
자본화:     |  볼륨(24시간):